CAS 142217-77-4
:(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purine-9-yl)-3-(benzyloxy)-2-(benzyloxyméthyl)cyclopentanol
- (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cydopentanol
- Entecavir intermediate N4
- (1S,2S,3S,5S)-5-(2-amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-((4-methylbenzyloxy)methyl)cyclopentanol
- Ent-4
- Intermediate of Entecavir 2
- (1S,2S,3S,5S)-5-(2-amino-6-(benzyloxyl)-9H-purin-9yl)-3-(benzyloxymethyl)cyclopentanol
- (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl) cyclopentanol
Cyclopentanol, 5-[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]-3-(phenylmethoxy)-2-[(phenylmethoxy)methyl]-, (1S,2S,3S,5S)-
CAS :Formule :C32H33N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :551.6355(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol
CAS :(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanolDegré de pureté :98%(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol
CAS :Degré de pureté :97%Masse moléculaire :551.64697265625(2R,3R,5R)-5-[2-Amino-6-(phenylmethoxy)-9H-purin-9-yl]-3-(phenylmethoxy)-2-[(phenylmethoxy)methyl]-cyclopentanol
CAS :Produit contrôléApplications (2R,3R,5R)-5-[2-Amino-6-(phenylmethoxy)-9H-purin-9-yl]-3-(phenylmethoxy)-2-[(phenylmethoxy)methyl]-cyclopentanol is an intermediate in the preparation of ent-Entecavir (E558905).
Formule :C32H33N5O4Couleur et forme :NeatMasse moléculaire :551.635(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol
CAS :(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol is a synthetic compound that is used to treat patients with chronic myeloid leukemia. It has been shown to inhibit tyrosine kinase and interacts with the guanine binding site of the purine nucleoside phosphorylase. This drug also inhibits the enzyme (deoxy)ribonucleotide reductase and competes with adenosine for binding to adenosine receptors. The stereoisomers of this drug are active against chronic myeloid leukemia cells. The S enantiomer is more potent than the R enantiomer and exhibits greater selectivity for leukemic cells than healthy cells. It has also been shown to inhibit nitric oxide synthase and may have anti-
Formule :C32H33N5O4Degré de pureté :Min. 95%Couleur et forme :White PowderMasse moléculaire :551.64 g/mol






